AMAG Pharmaceuticals Company Profile (NASDAQ:AMAG)

About AMAG Pharmaceuticals

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc. is a pharmaceutical company. The Company's segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse. It is engaged in the development of Digoxin immune fab, a polyclonal antibody for the treatment of severe preeclampsia in pregnant women. Makena is a drug indicated to reduce the risk of preterm birth in women pregnant with a single baby having a history of singleton spontaneous preterm birth.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AMAG
  • CUSIP: 00163U10
Key Metrics:
  • Previous Close: $23.30
  • 50 Day Moving Average: $23.74
  • 200 Day Moving Average: $26.95
  • 52-Week Range: $17.92 - $36.83
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 6.87
  • P/E Growth: -0.30
  • Market Cap: $827.57M
  • Outstanding Shares: 34,339,000
  • Beta: 1.09
Profitability:
  • Net Margins: 3.12%
  • Return on Equity: 11.10%
  • Return on Assets: 4.13%
Debt:
  • Debt-to-Equity Ratio: 0.99%
  • Current Ratio: 2.24%
  • Quick Ratio: 2.12%
Additional Links:
Companies Related to AMAG Pharmaceuticals:

Analyst Ratings

Consensus Ratings for AMAG Pharmaceuticals (NASDAQ:AMAG) (?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $31.78 (31.86% upside)

Analysts' Ratings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Show:
DateFirmActionRatingPrice TargetDetails
2/27/2017Cantor FitzgeraldSet Price TargetHold$24.00View Rating Details
2/15/2017Jefferies Group LLCReiterated RatingBuy$45.00 -> $40.00View Rating Details
2/3/2017Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 -> $28.00View Rating Details
1/31/2017J P Morgan Chase & CoSet Price TargetHold$24.00View Rating Details
1/11/2017Needham & Company LLCDowngradeBuy -> HoldView Rating Details
1/10/2017Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details
1/10/2017Leerink SwannDowngradeOutperform -> Market Perform$39.00 -> $25.00View Rating Details
1/9/2017Raymond James Financial, Inc.Reiterated RatingMarket Perform -> UnderperformView Rating Details
5/9/2016Deutsche Bank AGLower Price TargetHold$42.00 -> $35.00View Rating Details
3/28/2016Robert W. BairdLower Price TargetOutperform$26.00 -> $25.00View Rating Details
3/28/2016Ladenburg Thalmann Financial ServicesDowngradeBuy -> NeutralView Rating Details
1/28/2016Northland SecuritiesInitiated CoverageOutperform$40.00View Rating Details
1/21/2016Barclays PLCInitiated CoverageEqual Weight$32.00View Rating Details
(Data available from 2/28/2015 forward)

Earnings

Earnings History for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017        
2/14/2017Q416$1.85($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21$1.02$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
2/9/2015Q414$0.30$0.06$52.69 million$53.30 millionViewListenView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AMAG Pharmaceuticals (NASDAQ:AMAG)
Current Year EPS Consensus Estimate: $6.49 EPS
Next Year EPS Consensus Estimate: $3.51 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165$0.13$0.68$0.36
Q2 20163$0.14$0.76$0.54
Q3 20163$0.38$0.90$0.71
Q4 20162$0.32$0.44$0.38
Q1 20171($1.05)($1.05)($1.05)
Q2 20171$0.58$0.58$0.58
Q3 20171$0.43$0.43$0.43
Q4 20171$0.57$0.57$0.57
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AMAG Pharmaceuticals (NASDAQ:AMAG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Insider Ownership Percentage: 2.30%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2016Julie KropSVPSell4,938$24.80$122,462.40View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.00View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.00View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AMAG Pharmaceuticals (NASDAQ:AMAG)
DateHeadline
streetinsider.com logoAMAG Pharma (AMAG), Palatin (PTN) Announce Rekynda Data Presentations at ISSWSH Meeting - StreetInsider.com (NASDAQ:AMAG)
www.streetinsider.com - February 27 at 3:38 PM
finance.yahoo.com logo8:05 am AMAG Pharma and Palatin Technologies (PTN (NASDAQ:AMAG)
finance.yahoo.com - February 27 at 3:38 PM
News IconAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Target Price At $32.444 - Transcript Daily (NASDAQ:AMAG)
transcriptdaily.com - February 27 at 7:10 AM
News IconEPS Target Of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG)Set At ... - Transcript Daily (NASDAQ:AMAG)
transcriptdaily.com - February 24 at 8:44 PM
News IconRevenue Update on AMAG Pharmaceuticals(NASDAQ:AMAG) - Money Flow Index & Trends (NASDAQ:AMAG)
www.moneyflowtrends.com - February 24 at 3:41 PM
News IconTrading Circle: Narrowing in on Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - Midway Monitor (NASDAQ:AMAG)
midwaymonitor.com - February 24 at 3:41 PM
News IconNews Impact Score Of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) At 91 - Stock Observer (NASDAQ:AMAG)
www.thestockobserver.com - February 24 at 3:41 PM
finance.yahoo.com logoAMAG PHARMACEUTICALS INC. Financials (NASDAQ:AMAG)
finance.yahoo.com - February 24 at 3:41 PM
News IconANI Pharmaceuticals Inc (ANIP) Cut to "Neutral" at Roth Capital (NASDAQ:AMAG)
www.graffiotech.com - February 23 at 3:30 PM
News IconAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Price Target Set At $32.444 - Transcript Daily (NASDAQ:AMAG)
transcriptdaily.com - February 22 at 3:31 PM
moodys.com logoAMAG Pharmaceuticals, Inc. -- Moody's revises outlook on AMAG to stable, affirms B2 CFR (NASDAQ:AMAG)
www.moodys.com - February 22 at 11:33 AM
News IconTrading Watch: Checking in on Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) - BVN (NASDAQ:AMAG)
bvnewsjournal.com - February 21 at 3:46 PM
biz.yahoo.com logoAMAG PHARMACEUTICALS INC. Files SEC form 10-K, Annual Report (NASDAQ:AMAG)
biz.yahoo.com - February 21 at 7:16 AM
News IconAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Price Target At ... - Transcript Daily (NASDAQ:AMAG)
transcriptdaily.com - February 18 at 3:28 PM
marketexclusive.com logoAMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:AMAG)
marketexclusive.com - February 16 at 8:35 PM
marketexclusive.com logoAMAG PHARMACEUTICALS, INC. (NASDAQ:AMAG) Files An 8-K Entry into a Material Definitive Agreement (NASDAQ:AMAG)
marketexclusive.com - February 16 at 8:35 PM
investopedia.com logoAMAG Pharmaceuticals Inks $60M Drug Deal (NASDAQ:AMAG)
www.investopedia.com - February 16 at 3:33 PM
capitalcube.com logoAMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: 2016 By the Numbers : February 16, 2017 (NASDAQ:AMAG)
www.capitalcube.com - February 16 at 3:33 PM
finance.yahoo.com logoAMAG Pharma (AMAG) Incurs Loss in Q4, Revenues Lag Estimates (NASDAQ:AMAG)
finance.yahoo.com - February 16 at 8:24 AM
capitalcube.com logoAMAG Pharmaceuticals, Inc. :AMAG-US: Earnings Analysis: Q4, 2016 By the Numbers : February 15, 2017 (NASDAQ:AMAG)
www.capitalcube.com - February 16 at 8:24 AM
finance.yahoo.com logoEdited Transcript of AMAG earnings conference call or presentation 14-Feb-17 1:00pm GMT (NASDAQ:AMAG)
finance.yahoo.com - February 15 at 2:08 AM
seekingalpha.com logoAMAG Pharmaceuticals, Inc. 2016 Q4 - Results - Earnings Call Slides (NASDAQ:AMAG)
seekingalpha.com - February 14 at 9:08 PM
reuters.com logoBRIEF-Amag Pharmaceuticals, Endoceutics enter into license agreement (NASDAQ:AMAG)
www.reuters.com - February 14 at 9:08 PM
us.rd.yahoo.com logoAMAG and Endoceutics Enter Into an Exclusive U.S. License Agreement for Intrarosa™ (Prasterone) (NASDAQ:AMAG)
us.rd.yahoo.com - February 14 at 9:08 PM
us.rd.yahoo.com logoAMAG Reports Fourth Quarter and Full Year 2016 Financial Results (NASDAQ:AMAG)
us.rd.yahoo.com - February 14 at 9:08 PM
biz.yahoo.com logoQ4 2016 AMAG Pharmaceuticals Inc Earnings Release - Before Market Open (NASDAQ:AMAG)
us.rd.yahoo.com - February 14 at 9:08 PM
biz.yahoo.com logoAMAG PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Results of Operations and F (NASDAQ:AMAG)
us.rd.yahoo.com - February 14 at 9:08 PM
us.rd.yahoo.com logo7:20 am AMAG Pharma enters into an exclusive license agreement with Endoceutics that provides AMAG with U.S. commercial rights to Intrarosa; will pay Endoceutics $50 million of total upfront consideration and issue Endoceutics 600,000 unreg (NASDAQ:AMAG)
us.rd.yahoo.com - February 14 at 9:08 PM
finance.yahoo.com logoAMAG Pharmaceuticals reports 4Q loss - Yahoo Finance (NASDAQ:AMAG)
finance.yahoo.com - February 14 at 4:06 PM
streetinsider.com logoAMAG Pharma (AMAG), Endoceutics Enter License Agreement for Intrarosa - StreetInsider.com (NASDAQ:AMAG)
www.streetinsider.com - February 14 at 4:06 PM
nasdaq.com logoEarnings Reaction History: AMAG Pharmaceuticals, Inc, 20.0% Follow-Through Indicator, 5.1% Sensitive - Nasdaq (NASDAQ:AMAG)
www.nasdaq.com - February 14 at 4:06 PM
sg.finance.yahoo.com logoAMAG Pharmaceuticals reports 4Q loss (NASDAQ:AMAG)
sg.finance.yahoo.com - February 14 at 4:06 PM
biz.yahoo.com logoAMAG Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today (NASDAQ:AMAG)
biz.yahoo.com - February 14 at 4:06 PM
thestreet.com logoBiotech Premarket Movers: Pacific Biosciences of California, AMAG, Global Blood Therapeutics (NASDAQ:AMAG)
www.thestreet.com - February 14 at 4:06 PM
biz.yahoo.com logoAMAG Pharmaceuticals Inc Earnings Call (Q4 2016) (NASDAQ:AMAG)
biz.yahoo.com - February 13 at 9:01 PM
nasdaq.com logoAMAG Pharmaceuticals to Present at Upcoming Investor Conference - Nasdaq (NASDAQ:AMAG)
www.nasdaq.com - February 11 at 3:27 PM
nasdaq.com logoPerrigo Company (PRGO) Q4 Earnings: Disappointment in Store? (NASDAQ:AMAG)
www.nasdaq.com - February 10 at 9:02 PM
News IconAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Mean Price Target At ... - Transcript Daily (NASDAQ:AMAG)
transcriptdaily.com - February 10 at 3:57 PM
gurufocus.com logoAMAG Pharmaceuticals to Present at Upcoming Investor ... - GuruFocus.com (NASDAQ:AMAG)
www.gurufocus.com - February 10 at 3:57 PM
News IconAMAG Pharmaceuticals to Present at Upcoming Investor Conference - EconoTimes (NASDAQ:AMAG)
www.econotimes.com - February 9 at 3:31 PM
finance.yahoo.com logoAMAG Pharmaceuticals to Present at Upcoming Investor Conference (NASDAQ:AMAG)
finance.yahoo.com - February 9 at 3:31 PM
nasdaq.com logoAMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 ... - Nasdaq (NASDAQ:AMAG)
www.nasdaq.com - February 8 at 3:40 PM
finance.yahoo.com logoAMAG Pharmaceuticals to Host Fourth Quarter and Full Year 2016 Financial Results Conference Call and Webcast on Tuesday, February 14, 2017 at 8:00 a.m. ET (NASDAQ:AMAG)
finance.yahoo.com - February 7 at 3:57 PM
prnewswire.com logoResearch Reports Initiation on Healthcare Stocks -- Palatin Technologies, AMAG Pharma, IDEXX Labs, and Delcath ... - PR Newswire (press release) (NASDAQ:AMAG)
www.prnewswire.com - February 6 at 3:31 PM
News IconAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Target Price At $33.111 - Transcript Daily (NASDAQ:AMAG)
transcriptdaily.com - February 6 at 1:31 AM
streetinsider.com logoPalatin Technologies (PTN) Closes License Agreement for Rekynda ... - StreetInsider.com (NASDAQ:AMAG)
www.streetinsider.com - February 5 at 1:36 AM
News IconMetroWest Business Briefs for Feb. 4, 2017 - MetroWest Daily News (NASDAQ:AMAG)
www.metrowestdailynews.com - February 4 at 3:33 PM
investingnews.com logoAMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™ (NASDAQ:AMAG)
investingnews.com - February 3 at 9:26 PM
News IconNews Impact Score Of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) At 85 - Stock Observer (NASDAQ:AMAG)
www.thestockobserver.com - February 3 at 3:36 PM
News IconAMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) declared EPS of 1.78 - The Newburgh Press (NASDAQ:AMAG)
newburghpress.com - February 3 at 3:36 PM

Social

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

Where is AMAG Pharmaceuticals' stock going? Where will AMAG Pharmaceuticals' stock price be in 2017?

12 equities research analysts have issued 12 month price objectives for AMAG Pharmaceuticals' shares. Their predictions range from $24.00 to $45.00. On average, they expect AMAG Pharmaceuticals' stock price to reach $31.78 in the next year.

When will AMAG Pharmaceuticals announce their earnings?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 1st 2017.

What are analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:

  • Jefferies Group LLC analysts commented, "No surprise vs. pre-announced 4Q16 results on 1/9/17. Another acquisition of women's health product Intrarosa also fails to excite investors (following Rekynda on 1/9/17). Given ongoing concerns, near-term we view limited upside; medium/long-term share price recovery would likely be driven by timely approval/successful launch of Makena 3.0 & strong Intrarosa uptake providing confidence in its commercial potential, which may not be materialized until ~2018." (2/15/2017)
  • Guggenheim analysts commented, "Despite near-term setbacks, we continue to believe patience will be rewarded for AMAG investors with a longer-term horizon. However we are lowering our price target to $28 from $42. Our PT reduction is driven by lowered expectations for Makena life cycle extension. We believe Makena Sub-Q will face a challenging reimbursement environment, if approved, given the pain and Cmax PK data released this morning and expect generics to capture the majority of the market from '18+. Longer term stock price appreciation could be driven by Feraheme label expansion, CBR durability, Business Development, and Rekynda keep us positive." (2/2/2017)
  • Cantor Fitzgerald analysts commented, "Rekindling desire with Rekynda. On January 9, AMAG announced that it obtained a North American licensing from Palatin Technologies (PTN, not covered) for Rekynda to treat hypoactive sexual desire disorder (HSDD) in pre- menopausal women. Safety and efficacy were established in two Phase 3 clinical trials and AMAG expects to file an NDA in early 2018. HSDD market is large and lacking in effective treatments. AMAG believes the U.S. population of patients with HSDD is 15 million, 5.8 million of which are pre-menopausal. An estimated 800,000 women are being treated for HSDD and 2.2 million are diagnosed but not treated." (1/20/2017)

  • According to Zacks Investment Research, "We are concerned about AMAG’s dependence on sales of Makena, which primarily drives the company’s top line. We are also concerned about the company’s iron replacement therapy, Feraheme, which faces patent challenge in the U.S. In addition, inclusion of a boxed warning in Feraheme’s label is concerning. Moreover, termination of the marketing agreement with Takeda is a major setback for the company. Stiff competition and generic threats remain a woe as well. Estimates are stable ahead the company’s Q4 release. The company has recorded an average negative earnings surprise over the four trailing quarters. However, AMAG’s shares have outperformed the Medical-Biomedical/Genetics industry in the past one year." (1/9/2017)

Who owns AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Patrick Lee, MD (9.78%), Palo Alto Investors LLC (9.78%), Janus Capital Management LLC (9.55%), State Street Corp (4.21%), Numeric Investors LLC (2.74%) and Renaissance Technologies LLC (1.50%). Company insiders that own AMAG Pharmaceuticals stock include Frank E Thomas, John A Fallon, Julie Krop, Scott A Holmes and William K Heiden.

Who sold AMAG Pharmaceuticals stock? Who is selling AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Janus Capital Management LLC, Putnam Investments LLC, Oxford Asset Management, Kingdon Capital Management L.L.C., GRT Capital Partners L.L.C., AQR Capital Management LLC and GSA Capital Partners LLP.

Who bought AMAG Pharmaceuticals stock? Who is buying AMAG Pharmaceuticals stock?

AMAG Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Numeric Investors LLC, Russell Investments Group Ltd., Bogle Investment Management L P DE, Arrowstreet Capital Limited Partnership, Systematic Financial Management LP, Federated Investors Inc. PA and A.R.T. Advisors LLC.

How do I buy AMAG Pharmaceuticals stock?

Shares of AMAG Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of AMAG Pharmaceuticals stock cost?

One share of AMAG Pharmaceuticals stock can currently be purchased for approximately $24.10.

AMAG Pharmaceuticals (NASDAQ:AMAG) Chart for Tuesday, February, 28, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Earnings History Chart

Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Dividend History Chart

Dividend Payments by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Last Updated on 2/28/2017 by MarketBeat.com Staff